MARK4
Basic information
Region (hg38): 19:45079288-45305284
Previous symbols: [ "MARKL1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MARK4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 4 | |||||
missense | 41 | 41 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 0 | |||||
Total | 0 | 0 | 43 | 0 | 2 |
Variants in MARK4
This is a list of pathogenic ClinVar variants found in the MARK4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-45090133-A-G | not specified | Uncertain significance (May 30, 2024) | ||
19-45090164-G-T | not specified | Uncertain significance (May 14, 2024) | ||
19-45090198-T-A | not specified | Uncertain significance (Nov 13, 2023) | ||
19-45090230-C-T | not specified | Uncertain significance (Oct 05, 2022) | ||
19-45090254-C-T | not specified | Likely benign (Aug 17, 2022) | ||
19-45090262-T-A | not specified | Uncertain significance (Feb 14, 2023) | ||
19-45090420-C-G | not specified | Uncertain significance (May 31, 2023) | ||
19-45090457-G-A | not specified | Uncertain significance (Nov 08, 2021) | ||
19-45093360-C-T | not specified | Uncertain significance (Oct 29, 2021) | ||
19-45093416-G-T | not specified | Uncertain significance (Jun 21, 2023) | ||
19-45093471-C-G | not specified | Uncertain significance (Apr 22, 2022) | ||
19-45138552-A-C | not specified | Uncertain significance (Mar 29, 2022) | ||
19-45138561-T-A | not specified | Uncertain significance (Oct 27, 2022) | ||
19-45138588-C-G | not specified | Uncertain significance (Dec 01, 2022) | ||
19-45140251-G-A | not specified | Uncertain significance (Jan 04, 2022) | ||
19-45140263-G-A | not specified | Uncertain significance (Oct 26, 2022) | ||
19-45140521-A-G | not specified | Uncertain significance (Oct 30, 2023) | ||
19-45140527-C-T | not specified | Uncertain significance (Jun 10, 2024) | ||
19-45141381-C-G | not specified | Uncertain significance (Jul 20, 2022) | ||
19-45142089-G-A | not specified | Uncertain significance (May 23, 2023) | ||
19-45142095-C-T | not specified | Uncertain significance (May 11, 2022) | ||
19-45142116-C-T | not specified | Uncertain significance (May 22, 2023) | ||
19-45142124-G-T | not specified | Uncertain significance (Mar 18, 2024) | ||
19-45142130-C-T | not specified | Uncertain significance (Oct 26, 2022) | ||
19-45142133-G-A | not specified | Uncertain significance (Feb 28, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MARK4 | protein_coding | protein_coding | ENST00000262891 | 17 | 225996 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.998 | 0.00223 | 125737 | 0 | 11 | 125748 | 0.0000437 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.92 | 312 | 495 | 0.630 | 0.0000343 | 4776 |
Missense in Polyphen | 95 | 165.01 | 0.57571 | 1584 | ||
Synonymous | 0.315 | 205 | 211 | 0.972 | 0.0000146 | 1612 |
Loss of Function | 4.90 | 4 | 35.5 | 0.113 | 0.00000192 | 397 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000178 | 0.000178 |
Ashkenazi Jewish | 0.0000998 | 0.0000992 |
East Asian | 0.00 | 0.00 |
Finnish | 0.0000503 | 0.0000462 |
European (Non-Finnish) | 0.0000264 | 0.0000264 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.000164 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Serine/threonine-protein kinase (PubMed:15009667, PubMed:14594945, PubMed:23666762, PubMed:23184942). Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:14594945, PubMed:23666762). Also phosphorylates the microtubule-associated proteins MAP2 and MAP4 (PubMed:14594945). Involved in regulation of the microtubule network, causing reorganization of microtubules into bundles (PubMed:14594945, PubMed:25123532). Required for the initiation of axoneme extension during cilium assembly (PubMed:23400999). Regulates the centrosomal location of ODF2 and phosphorylates ODF2 in vitro (PubMed:23400999). Plays a role in cell cycle progression, specifically in the G1/S checkpoint (PubMed:25123532). Reduces neuronal cell survival (PubMed:15009667). Plays a role in energy homeostasis by regulating satiety and metabolic rate (By similarity). Promotes adipogenesis by activating JNK1 and inhibiting the p38MAPK pathway, and triggers apoptosis by activating the JNK1 pathway (By similarity). Phosphorylates mTORC1 complex member RPTOR and acts as a negative regulator of the mTORC1 complex, probably due to disruption of the interaction between phosphorylated RPTOR and the RRAGA/RRAGC heterodimer which is required for mTORC1 activation (PubMed:23184942). {ECO:0000250|UniProtKB:Q8CIP4, ECO:0000269|PubMed:14594945, ECO:0000269|PubMed:15009667, ECO:0000269|PubMed:23184942, ECO:0000269|PubMed:23400999, ECO:0000269|PubMed:23666762, ECO:0000269|PubMed:25123532}.;
- Pathway
- Anchoring of the basal body to the plasma membrane;LKB1 signaling events;Cilium Assembly;Organelle biogenesis and maintenance
(Consensus)
Recessive Scores
- pRec
- 0.140
Intolerance Scores
- loftool
- 0.0914
- rvis_EVS
- -0.98
- rvis_percentile_EVS
- 8.75
Haploinsufficiency Scores
- pHI
- 0.540
- hipred
- Y
- hipred_score
- 0.806
- ghis
- 0.567
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.930
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mark4
- Phenotype
- behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); homeostasis/metabolism phenotype; growth/size/body region phenotype;
Gene ontology
- Biological process
- microtubule cytoskeleton organization;microtubule bundle formation;protein phosphorylation;cell cycle;nervous system development;establishment of cell polarity;intracellular signal transduction;positive regulation of programmed cell death;cilium organization;positive regulation of cilium assembly;regulation of centrosome cycle;cell division;ciliary basal body-plasma membrane docking;positive regulation of protein localization to centrosome
- Cellular component
- gamma-tubulin complex;cytoplasm;centrosome;microtubule organizing center;cytosol;microtubule cytoskeleton;dendrite;midbody;ciliary basal body;neuron projection
- Molecular function
- protein serine/threonine kinase activity;protein binding;ATP binding;microtubule binding;gamma-tubulin binding;ubiquitin binding;tau protein binding;tau-protein kinase activity